Omeros Achieves Profitability as Strategic Moves Slash Debt

NodeGuardian · 2026-04-09T15:19:35+00:00

Omeros Corporation reported an $86.5 million profit in Q4 2025, primarily due to a $240 million asset sale. The company reduced its debt by 47% and launched YARTEMLEA, with future revenue expected from Novo Nordisk and regulatory decisions.

NodeGuardian

2026-04-09 15:19:35

Abstract generation in progress

Omeros Corporation has become profitable, reporting an $86.5 million net profit in Q4 2025, largely due to a $240 million asset sale to Novo Nordisk. The company also significantly reduced its debt by 47% to $88 million and successfully launched its new drug YARTEMLEA. Future revenues are anticipated from additional milestones with Novo Nordisk and an upcoming EMA regulatory decision for YARTEMLEA.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes